
Steven W Pipe MD
Pediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology
Professor, Pediatrics & Communicable Diseases, University of Michigan Medical School
Join to View Full Profile
1500 E Medical Center DrD4207 MPBAnn Arbor, MI 48109
Phone+1 734-232-9335
Fax+1 734-615-0464
Dr. Pipe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Pipe is a Pediatric Hematology & Oncology specialist based in Ann Arbor, MI. He completed his Medical Education at University of Toronto Faculty of Medicine in 1989, pediatric residency at McMaster University in Hamilton and his Fellowship in Pediatric Hematology/Oncology at the University of Michigan from 1993 - 1996. Dr. Pipe's areas of expertise are hemostasis and thrombosis, with a particular focus on inherited bleeding disorders. His research work has been published in several high-rated medical journals, such as The New England Journal of Medicine, Lancet, Blood and the Journal of Thrombosis and Haemostasis, with broad citation by other publications. He has been involved in several clinical trials focusing on novel therapeutics and gene therapy in patients with hemophilia.
Education & Training
- University of MichiganFellowship, Pediatric Hematology/Oncology, 1993 - 1996
- University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
- MI State Medical License 1996 - 2025
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Dose Confirmation Trial of AAV5-hFIXco-Padua Start of enrollment: 2018 Jul 24
- HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients Start of enrollment: 2018 Jun 27
- Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors Start of enrollment: 2019 Jan 30
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials.Guy Young, Johnny Mahlangu, Lisa N Boggio, Manuel Carcao, Yesim Dargaud
Blood Vessels, Thrombosis & Hemostasis. 2025-08-01 - 2 citationsCompletion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years.Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S Key
Blood Advances. 2025-07-22 - Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors.Tyler W Buckner, Craig Kessler, Giancarlo Castaman, Cédric Hermans, Victor Jiménez-Yuste
Haemophilia. 2025-07-01
Abstracts/Posters
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BSteven Pipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- Positive Follow-up Results in Patients with Hemophilia B Given Gene Therapy (Hemgenix)March 19th, 2025
- Etranacogene Dezaparvovec Shows Long-Term Bleed Protection, SafetyMarch 13th, 2025
- CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia BFebruary 9th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: